Bexxar

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1999-2016
0519992016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Conventional chemotherapy with small molecule drugs has been used for many types of cancer for decades. However, the therapeutic… (More)
  • figure 1
  • figure 3
  • figure 4
  • figure 2
Is this relevant?
Review
2010
Review
2010
Radioimmunotherapy is a form of targeted radionuclide therapy that uses a monoclonal antibody to deliver localized radiation. It… (More)
  • figure 1
  • figure 2
  • figure 2
  • figure 4
  • figure 5
Is this relevant?
2006
2006
We present the long-term results of 18 chemotherapy relapsed indolent (N=12) or transformed (N=6) NHL patients of a phase II anti… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2006
2006
The role of nuclear medicine in oncology has changed dramatically in recent years owing to outstanding technical advances in… (More)
  • figure 1
Is this relevant?
Highly Cited
2005
Highly Cited
2005
PURPOSE To determine overall response (OR) and complete response (CR) rates, response duration, progression-free (PFS) and… (More)
Is this relevant?
2004
2004
6518 Background: The sequential combination of chemotherapy and radioimmunotherapy offers a novel strategy for the initial… (More)
Is this relevant?
2004
2004
6575 Introduction: The Bexxar therapeutic regimen can produce durable and complete responses in patients with relapsed/refractory… (More)
Is this relevant?
2004
2004
6520 Background: A phase II, open-label, multicenter study was conducted to determine the efficacy of Bexxar therapy following… (More)
Is this relevant?
Review
2002
Review
2002
Bexxar (131I tositumomab) is a radiolabeled anti-CD20 monoclonal antibody for the treatment of relapsed and refractory follicular… (More)
Is this relevant?
2002
2002
BACKGROUND Radioimmunotherapy (RIT) with Bexxar (tositumomab and iodine-131 tositumomab; Coulter Pharmaceutical, South San… (More)
Is this relevant?